PL2691376T3 - Związki kompleksowe żelaza(III) do leczenia i profilaktyki objawów niedoboru żelaza i anemii uwarunkowanych niedoborem żelaza - Google Patents

Związki kompleksowe żelaza(III) do leczenia i profilaktyki objawów niedoboru żelaza i anemii uwarunkowanych niedoborem żelaza

Info

Publication number
PL2691376T3
PL2691376T3 PL12711629T PL12711629T PL2691376T3 PL 2691376 T3 PL2691376 T3 PL 2691376T3 PL 12711629 T PL12711629 T PL 12711629T PL 12711629 T PL12711629 T PL 12711629T PL 2691376 T3 PL2691376 T3 PL 2691376T3
Authority
PL
Poland
Prior art keywords
iron deficiency
prophylaxis
complexes
iii
treatment
Prior art date
Application number
PL12711629T
Other languages
English (en)
Inventor
Thomas Bark
Wilm Buhr
Susanna Burckhardt
Michael Burgert
Camillo Canclini
Franz Dürrenberger
Felix Funk
Peter Otto Geisser
Aris Kalogerakis
Simona Mayer
Erik Philipp
Stefan Reim
Diana Sieber
Jörg Schmitt
Katrin Schwarz
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44140927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2691376(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of PL2691376T3 publication Critical patent/PL2691376T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12711629T 2011-03-29 2012-03-28 Związki kompleksowe żelaza(III) do leczenia i profilaktyki objawów niedoboru żelaza i anemii uwarunkowanych niedoborem żelaza PL2691376T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11160151 2011-03-29
EP12711629.1A EP2691376B1 (de) 2011-03-29 2012-03-28 Fe(iii)-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien
PCT/EP2012/055512 WO2012130882A1 (de) 2011-03-29 2012-03-28 Fe(iii)-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien

Publications (1)

Publication Number Publication Date
PL2691376T3 true PL2691376T3 (pl) 2016-06-30

Family

ID=44140927

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12711629T PL2691376T3 (pl) 2011-03-29 2012-03-28 Związki kompleksowe żelaza(III) do leczenia i profilaktyki objawów niedoboru żelaza i anemii uwarunkowanych niedoborem żelaza

Country Status (32)

Country Link
US (1) US9422247B2 (pl)
EP (1) EP2691376B1 (pl)
JP (1) JP5923161B2 (pl)
KR (1) KR101889050B1 (pl)
CN (1) CN103429575B (pl)
AR (1) AR085736A1 (pl)
AU (1) AU2012234292B2 (pl)
BR (1) BR112013024722B1 (pl)
CA (1) CA2829240C (pl)
CL (1) CL2013002766A1 (pl)
CO (1) CO6811850A2 (pl)
CR (1) CR20130485A (pl)
DK (1) DK2691376T3 (pl)
DO (1) DOP2013000213A (pl)
EA (1) EA026192B1 (pl)
EC (1) ECSP13012904A (pl)
ES (1) ES2560964T3 (pl)
GT (1) GT201300224A (pl)
HU (1) HUE026712T2 (pl)
IL (1) IL228502A (pl)
MA (1) MA34977B1 (pl)
MX (1) MX358194B (pl)
MY (1) MY168952A (pl)
PE (1) PE20141319A1 (pl)
PH (1) PH12013501968A1 (pl)
PL (1) PL2691376T3 (pl)
PT (1) PT2691376E (pl)
SG (1) SG193981A1 (pl)
TN (1) TN2013000379A1 (pl)
TW (1) TWI510496B (pl)
WO (1) WO2012130882A1 (pl)
ZA (1) ZA201308050B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246473B (zh) 2012-12-21 2018-07-13 维福(国际)股份有限公司 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物
CN103951552B (zh) * 2014-04-11 2015-09-30 浙江宏元药业有限公司 瑞舒伐他汀中间体及其制备方法
RU2625739C1 (ru) * 2016-09-28 2017-07-18 Общество с ограниченной ответственностью Научно-производственное предприятие "Эксорб" Фармакологическая композиция на основе соединений железа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474670A (en) 1892-05-10 Automatic fire-alarm
GB842637A (en) 1955-12-27 1960-07-27 Andre Georges Jules Jallais Glass frames, more especially for forced cultivation
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8410289D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
IT1222654B (it) 1987-09-14 1990-09-12 Schering Ag Complesso micellare di ferro-citrato
JPH0283400A (ja) 1988-09-21 1990-03-23 Snow Brand Milk Prod Co Ltd 鉄カゼインの製造方法
ES2044777B1 (es) 1992-03-03 1994-08-01 Dabeer Sa Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
US20030236224A1 (en) 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
DE10253843B3 (de) 2002-11-14 2004-05-06 Bizerba Gmbh & Co. Kg Etikettiervorrichtung für bewegte Gegenstände und Verfahren zur Etikettierung von bewegten Gegenständen
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
ZA200702421B (en) 2004-10-08 2008-09-25 Unilever Plc Iron complex for use in the treatment and/or prevention of nutritional disorders
US20090035385A1 (en) 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
CN100443485C (zh) 2005-04-08 2008-12-17 吴华君 叶绿酸合铁钠盐衍生物、制备方法及用途
JP4948056B2 (ja) * 2005-09-02 2012-06-06 月桂冠株式会社 疲労の予防又は改善剤
WO2007062546A1 (fr) 2005-11-30 2007-06-07 Chongqing Pharmaceutical Research Institute Co., Ltd. Complexes fer-saccharide faciles a reconstituer et leur procede de fabrication
FR2916592B1 (fr) 2007-05-25 2017-04-14 Groupe Des Ecoles De Telecommunications(Get)-Ecole Nat Superieure Des Telecommunications(Enst) Procede de securisation d'echange d'information,dispositif, et produit programme d'ordinateur correspondant
CN101481404B (zh) 2008-12-17 2011-10-05 中国农业大学 一种酶解乳蛋白亚铁络合物微胶囊补铁剂及其制备方法

Also Published As

Publication number Publication date
KR20140027196A (ko) 2014-03-06
DOP2013000213A (es) 2013-11-15
BR112013024722B1 (pt) 2022-04-12
SG193981A1 (en) 2013-11-29
IL228502A (en) 2015-02-26
ECSP13012904A (es) 2013-12-31
EA026192B1 (ru) 2017-03-31
EP2691376B1 (de) 2015-12-09
BR112013024722A2 (pt) 2016-12-20
KR101889050B1 (ko) 2018-08-20
ES2560964T3 (es) 2016-02-23
PT2691376E (pt) 2016-03-02
US9422247B2 (en) 2016-08-23
CA2829240A1 (en) 2012-10-04
TWI510496B (zh) 2015-12-01
AU2012234292A1 (en) 2013-10-17
WO2012130882A1 (de) 2012-10-04
ZA201308050B (en) 2016-01-27
CN103429575A (zh) 2013-12-04
CO6811850A2 (es) 2013-12-16
MX358194B (es) 2018-07-16
US20140162994A1 (en) 2014-06-12
HUE026712T2 (en) 2016-07-28
IL228502A0 (en) 2013-12-31
PH12013501968A1 (en) 2013-12-16
MY168952A (en) 2019-01-28
JP2014509624A (ja) 2014-04-21
CN103429575B (zh) 2016-08-31
JP5923161B2 (ja) 2016-05-24
TW201245212A (en) 2012-11-16
MX2013010964A (es) 2013-10-17
EA201301083A1 (ru) 2014-03-31
CA2829240C (en) 2016-11-22
NZ616045A (en) 2015-04-24
GT201300224A (es) 2015-01-20
PE20141319A1 (es) 2014-10-29
TN2013000379A1 (en) 2015-01-20
AR085736A1 (es) 2013-10-23
CL2013002766A1 (es) 2014-03-21
AU2012234292B2 (en) 2016-09-22
MA34977B1 (fr) 2014-03-01
EP2691376A1 (de) 2014-02-05
DK2691376T3 (en) 2016-02-15
CR20130485A (es) 2014-05-20

Similar Documents

Publication Publication Date Title
ZA201207550B (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
HUE052036T2 (hu) Vasat tartalmazó szilárd készítmény vashiányos állapotokban történõ kezelésre
GB2478595B (en) Phytocannabinoids in the treatment of glioma
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
LT2523661T (lt) Nkcc inhibitoriai autizmo gydymui
EP2877848A4 (en) METHOD FOR TREATING FERMENTED ANEMIA
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
SG2013062112A (en) Defect reduction in plasma processing
IL232648A0 (en) Preparations and methods for treating glioma
EP2825194A4 (en) USE OF ANTITHROMBINE IN THE TREATMENT OF PRE-ECLAMPSIA
PL3068384T3 (pl) Kompleksy żelaza do zmniejszania kolonizacji przewodu pokarmowego przez campylobacter
GB2509490B (en) Magnetic coupling and cancellation arrangement
AP3866A (en) Method for improving the reduction degree in the smelting of ferroalloy
EP2857553A4 (en) PROCESSING SOLUTION FOR CONVERTING THREE-QUALITY CHROMIUM WITH ALUMINUM-MODIFIED COLLOIDAL SILICA
PL2731616T3 (pl) Sposób profilaktyki i leczenia sepsy
PT2920156T (pt) Processo para a preparação de ligandos e quelatos macrocíclicos de poliazacarboxilato
PL2691376T3 (pl) Związki kompleksowe żelaza(III) do leczenia i profilaktyki objawów niedoboru żelaza i anemii uwarunkowanych niedoborem żelaza
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
IL235035A0 (en) A preparation to prevent an effect on blood vessels in the treatment of blood loss and anemia
EP2964205A4 (en) NOVEL IRON-BASED NANOCOMPOSITE FORMULA FOR RAPID AND EFFICIENT TREATMENT OF ANEMIA RELATED TO IRON FAILURE
EP2559432A4 (en) MEANS FOR THE PREVENTION AND TREATMENT OF ACUTE AND CHRONIC PANCREATITIS
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
MX2015013736A (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemia por deficiencia de hierro.
MX2015007974A (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro.
HK1175121A (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias